AGIOS PHARMACEUTICALS, INC. (AGIO) Stock
AGIO has an Alpha Score of 31 out of 100 (poor), computed on Nov 1, 2026 from 2 of 4 sub-scores. 3 members of Congress disclosed 7 trades in AGIO since 2015: 6 purchases and 1 sale, most recently Gilbert Cisneros (purchase, Aug 20, 2026). 4 of the hedge funds AlphaScala tracks reported AGIO in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $115.30M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
What is AGIO's Alpha Score?
How it works →Alpha Score of 31 reflects weak overall profile with weak momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 1, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded AGIOS PHARMACEUTICALS, INC. (AGIO)?
Most recent: Gilbert Cisneros (purchase, Aug 20, 2026); records start May 27, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-08-20 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-03 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-12-11 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-04-17 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-01-29 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-01-24 | purchase | $1k – $15k |
| Tom MacArthur R-NJ · House | 2015-05-27 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all AGIO political trades →Which hedge funds own AGIO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 3.11M | $115.30M | +16% |
| Citadel Ken Griffin | 733K | $27.19M | +18% |
| Point72 Steve Cohen | 506K | $18.79M | NEW |
| Marshall Wace | 139K | $5.15M | -69% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are AGIOS PHARMACEUTICALS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 26, 26 | Gheuens Sarah | Chief Medical Officer | SELL | 7.9K | $296K |
| Oct 22, 26 | Gheuens Sarah | Chief Medical Officer | SELL | 500 | $19K |
| Oct 21, 26 | Gheuens Sarah | Chief Medical Officer | SELL | 1.5K | $56K |
| Aug 4, 26 | Gheuens Sarah | Chief Medical Officer | SELL | 30.0K | $914K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are AGIO's key statistics?
Key statistics as of Nov 1, 2026
How does AGIO's valuation compare with the Healthcare sector?
| Metric | AGIO | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -418.24% | 4.31% | 164 |
| Return on equity | -35.67% | 5.47% | 185 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
AGIO price chart
Powered by TradingViewWhat does AGIOS PHARMACEUTICALS, INC. do?
Agios Pharmaceuticals Inc. is a biopharmaceutical company specializing in cellular metabolism to develop differentiated medicines for rare diseases, with a particular emphasis on classical hematology. The company focuses on creating potentially transformative small-molecule therapies targeting unmet medical needs in hemolytic anemias and related conditions. Its lead product, Pyrukynd (mitapivat), serves as an activator of both wild-type and mutant pyruvate kinase enzymes, addressing hemolytic anemias. The pipeline also features other candidates such as Tebapivat, a PK activator under development for MDS-associated anemia and sickle cell disease, along with AG-181, a PAH stabilizer, and AG-236. Agios Pharmaceuticals Inc. plays a vital role in advancing treatments for genetically defined rare diseases, leveraging expertise in metabolic pathways to innovate oral therapies that could alter disease progression for patients lacking effective options. Founded in 2007 and headquartered in Cambridge, Massachusetts, the company remains dedicated to this focused therapeutic area in the biopharmaceutical sector.